Jenscare Scientific Co., Ltd.

What Jenscare Scientific Co., Ltd. does

Jenscare Scientific Co., Ltd. is a China-headquartered, Hong Kong-listed (9877.HK) medical device company developing transcatheter valve replacement and repair systems for structural heart disease. Its core product portfolio comprises LuX-Valve Plus (transcatheter tricuspid valve replacement, or TTVR) for severe tricuspid regurgitation, Ken-Valve (transcatheter aortic valve replacement, or TAVR) for aortic regurgitation with or without aortic stenosis, and JensClip (transcatheter mitral valve repair) for mitral regurgitation. The portfolio targets patients with anatomies or risk profiles that make them poor candidates for conventional surgery — large aortic annuli, non-calcified aortic regurgitation, severe tricuspid disease (the so-called "forgotten valve"), and high-surgical-risk patients. Differentiated design elements include LuX-Valve Plus's leaflet grasping plus interventricular septal anchoring mechanism, Ken-Valve's integrated clamping/positioning mechanism with sealing skirt, and JensClip's self-locking one-piece release system.

In 2026 the company has been executing a globalization of its commercialization footprint: LuX-Valve Plus received EU MDR CE certification and initiated FDA IDE pivotal trial implantations in the United States; Ken-Valve secured Hong Kong Department of Health approval; and the robotic platform iJensRobo — co-developed with the Institute of Automation of the Chinese Academy of Sciences — completed a first-in-human TTVR study in Hong Kong. The go-to-market model is enterprise field sales into hospital cardiac surgery and interventional cardiology departments, supported by KOL engagement at international conferences (TCT, EuroPCR, PCR London Valves, New York Valves), physician training programs (50+ KOLs in China, 40+ abroad for LuX-Valve; 30+ Ken-Valve KOLs; 100+ MDT experts), and clinical-trial-led market development. Pricing is not publicly disclosed and is conducted via hospital procurement; revenue is not yet disclosed and the company reported a 178M RMB net loss in 2024 (down 52.2% year-over-year) against a 708M RMB cash balance, indicating a capital-intensive pre-/early-commercial phase backed by a 2022 Hong Kong IPO and a proposed A-share STAR Market listing.

Name

Jenscare Scientific Co., Ltd.

Legal name

Jenscare Scientific Co., Ltd.

Website

https://en.jenscare.com

Company type

Public

Operating status

Operating

Headcount range

11–50 employees

Short description

Jenscare Scientific is a Hong Kong-listed (9877.HK) China-based medical device company developing transcatheter valve replacement and repair systems — LuX-Valve Plus (tricuspid), Ken-Valve (aortic), and JensClip (mitral) — for high-risk structural heart disease patients, with international commercialization across China, Europe, the U.S., and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Structural Heart Disease Interventional Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

akta.pro secondary industries

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)

Keywords

• Transcatheter valve replacement
• Structural heart devices
• Cardiac intervention systems
• Mitral valve repair
• Tricuspid valve replacement

Headquarters

HQ city

Not specified

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Jenscare Scientific Co., Ltd. develops, manufactures, and commercializes transcatheter interventional medical devices for the treatment of structural heart diseases, including transcatheter aortic valve replacement (Ken-Valve), transcatheter tricuspid valve replacement (LuX-Valve Plus), transcatheter mitral valve repair (JensClip), and the iJensRobo robotic-assisted interventional platform. The products are sold to hospitals, cardiac surgery centers, and interventional cardiology departments globally.

Product overview

Jenscare Scientific Co., Ltd. is a medical device company developing innovative transcatheter devices for structural heart disease treatment. The company's product portfolio centers on three core valve replacement/repair systems: LuX-Valve Plus (transcatheter tricuspid valve replacement for severe tricuspid regurgitation), Ken-Valve (transcatheter aortic valve replacement for aortic regurgitation with/without stenosis), and JensClip (transcatheter mitral valve repair). Additionally, the company has developed the iJensRobo surgical robotics platform, created in partnership with the Institute of Automation of the Chinese Academy of Sciences, to enhance precision and control during interventional procedures. The portfolio addresses unmet clinical needs in valvular heart disease treatment through minimally invasive catheter-based approaches.

Differentiator

Problem solved

Functional benefit

Brands

• LuX-Valve Plus: Transcatheter tricuspid valve replacement (TTVR) system for severe tricuspid regurgitation
• Ken-Valve
• JensClip
• iJensRobo

Products and services

• LuX-Valve Plus Transcatheter tricuspid valve replacement (TTVR) system designed for patients with severe tricuspid regurgitation. Features a unique leaflet grasping plus interventricular septal anchoring mechanism for stable fixation in complex tricuspid valve anatomy. Demonstrated 96.87% implantation success rate, 98.83% TR reduction to moderate or less, and 85% NYHA class improvement in clinical trials. Sold to hospitals and cardiac surgery centers.
• Ken-Valve Transcatheter aortic valve replacement (TAVR) system designed for the treatment of aortic regurgitation (AR), with or without concomitant aortic stenosis (AS). Features integrated clamping and positioning mechanism, sealing skirt design to reduce paravalvular leak risk, proprietary anti-calcification treatment on bovine pericardial leaflets, and a steerable delivery system. Available in valve sizes 23mm to 33mm to accommodate patients with large annuli. Sold to hospitals and cardiac surgery centers.
• JensClip Transcatheter mitral valve repair (TMVr) system featuring an innovative self-locking design intended to effectively improve mitral regurgitation and reduce leaflet tension. Provides flexible shape adjustments, enhanced intraoperative maneuverability, and a one-piece release mechanism designed to minimize misoperation risks. Sold to hospitals and cardiac surgery centers.
• iJensRobo Robotic-Assisted Interventional Platform Robotic-assisted interventional platform developed in collaboration with the Institute of Automation of the Chinese Academy of Sciences. Provides high-precision motion control, active safety constraint mechanisms, and intelligent navigation technologies for transcatheter tricuspid valve replacement procedures. Features a master-slave architecture with remote operation capability that reduces physician radiation exposure and enhances procedural precision.

Quantifiable outcome

• 96.87% implantation success rate for LuX-Valve Plus in TRAVEL II study
• +4 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered major and core.

• Fuwai HospitalmajorStrategic or Co-development Partner · 22 April 2026Fuwai Hospital team led by Dr. Xiangbin Pan guided the first fully echocardiography-guided TAVR procedure at Tongliao People's Hospital. Developed the PAN technique for radiation-free ultrasound-guided interventional procedures.
• Institute of Automation of the Chinese Academy of SciencescoreTechnology or Integration · 17 April 2026Close collaboration on development of iJensRobo robotic-assisted interventional platform for TTVR procedures. Combines company's device expertise with the Institute's robotics and automation research capabilities.
• Hong Kong Innovation Institute of the Chinese Academy of SciencesmajorStrategic or Co-development Partner · 17 April 2026Supported the first-in-human clinical study of iJensRobo system at Prince of Wales Hospital, forming an innovation loop from technology development to clinical translation.
• Faculty of Medicine at The Chinese University of Hong KongmajorStrategic or Co-development Partner · 17 April 2026Supported the first-in-human clinical study of iJensRobo system, providing clinical translation support and academic partnership for the robotic TTVR platform.
• Lifetech Scientific CorporationcoreStrategic or Co-development Partner · 6 February 2023Strategic cooperation agreement signed in February 2023 for potential collaboration in structural heart disease treatment devices and related business development.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Global medical device leader with Evolut TAVR platform and Intrepid TTVR/TMVR programs. One of the two dominant players in TAVR globally and a major competitor in transcatheter valve replacement across all Jenscare's targeted indications.
• Abbott: Diversified medical device giant with structural heart franchise including Tendyne (TMVR) and MitraClip/TriClip (transcatheter edge-to-edge repair). Competes in transcatheter mitral and tricuspid repair with Jenscare's JensClip and LuX-Valve Plus offerings.
• Boston Scientific: Global medical device company with structural heart portfolio including ACURATE neo2 TAVR and ongoing TTVR programs (Intrepid). Competitor in transcatheter valve space with overlapping indications to Jenscare's portfolio.
• Edwards Lifesciences: Global structural heart leader with the dominant TAVR franchise (Sapien) and emerging TTVR programs (Evoque). Edwards is the gold-standard competitor in transcatheter valve replacement and a key benchmark for Jenscare's TAVR and TTVR devices.
• MicroPort Scientific: Chinese medical device conglomerate with structural heart programs including TAVR through its cardiovascular division. Major domestic competitor to Jenscare with broader product portfolio and larger commercial scale in China.

Emerging players

• 4C Medical Technologies: Early-stage company developing transcatheter tricuspid valve replacement technology (AltaValve system). Emerging player in TTVR space overlapping with LuX-Valve Plus's clinical focus on tricuspid regurgitation.
• Cardiovalve (owned by Venus MedTech): Transcatheter mitral and tricuspid valve replacement technology developed by Venus MedTech. Emerging player in transcatheter tricuspid space overlapping with LuX-Valve Plus, but acquired by direct peer Venus MedTech.

Direct peers

• Venus MedTech: Chinese structural heart company developing TAVR, TTVR, and TMVr devices with overlapping indications (aortic, tricuspid, mitral regurgitation). Closely comparable in product portfolio, geographic focus (China-led globalization), and competitive positioning to Jenscare.
• Peijia Medical: Chinese medical device company specializing in TAVR and TTVR systems with similar technology profile (transcatheter valve replacement for structural heart disease). Direct competitor in the China structural heart market with overlapping product portfolio.
• JenaValve Technology: Developer of transcatheter aortic valve replacement system specifically designed for aortic regurgitation (the ALIGN-AR trial). Direct competitor to Ken-Valve in the AR-focused TAVR niche with similar patient targeting strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jenscare

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jenscare Scientific Co., Ltd.